PRTKUnknown
Paratek Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Paratek Pharmaceuticals, Inc. (PRTK), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PRTK insiders buying or selling?
Paratek Pharmaceuticals, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since February 2018, Trabud has recorded 102 Form 4 filings for PRTK: 1 buys ($1.3M) and 101 sells ($8.0M).
Source: SEC EDGAR Form 4
Key Statistics (February 2018 – Aug 11, 2023)
Total Form 4 filings
102
SEC EDGAR
Insider filers
11
Insider buys (1)
$1.3M
Insider sells (101)
$8.0M
Insider sentiment
Net sellingNet insider flow of $6.7M in net selling since February 2018.
Recent PRTK insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 11, 2023 | Randall B. Brenner | Chief Development & Regulatory | Sale | 27.6K | $2.20 | $60.7K | SEC ↗ |
| Aug 11, 2023 | Michael Bigham | Exec. Chairman of the Board | Sale | 31.3K | $2.20 | $68.8K | SEC ↗ |
| Aug 11, 2023 | William M. Haskel | CLO, General Counsel & Sec. | Sale | 34.5K | $2.20 | $76.0K | SEC ↗ |
| Aug 11, 2023 | Evan Loh | CEO | Sale | 49.0K | $2.20 | $107.7K | SEC ↗ |
| Mar 29, 2023 | DONDERO JAMES D | 10% Owner | Purchase | 788.5K | $1.63 | $1.3M | SEC ↗ |
| Feb 23, 2023 | Jeffrey Stein | Director | Sale | 7.0K | $1.90 | $13.3K | SEC ↗ |
| Feb 23, 2023 | Timothy R Franson | Director | Sale | 7.0K | $1.88 | $13.2K | SEC ↗ |
| Dec 22, 2022 | Adam Woodrow | President & Chief Commercial | Sale | 6.8K | $1.99 | $13.4K | SEC ↗ |
| Dec 22, 2022 | Evan Loh | CEO | Sale | 23.5K | $1.99 | $46.7K | SEC ↗ |
| Dec 22, 2022 | William M. Haskel | CLO, General Counsel & Sec. | Sale | 7.0K | $1.99 | $13.9K | SEC ↗ |
| Dec 22, 2022 | Randall B. Brenner | Chief Development & Regulatory | Sale | 4.5K | $1.99 | $9.0K | SEC ↗ |
| Dec 22, 2022 | Michael Bigham | Exec. Chairman of the Board | Sale | 15.8K | $1.99 | $31.3K | SEC ↗ |
| Dec 15, 2022 | Adam Woodrow | President & Chief Commercial | Sale | 10.1K | $1.97 | $19.8K | SEC ↗ |
| Dec 15, 2022 | Evan Loh | CEO | Sale | 99.8K | $1.97 | $196.3K | SEC ↗ |
| Dec 15, 2022 | William M. Haskel | CLO, General Counsel & Sec. | Sale | 38.0K | $1.97 | $74.8K | SEC ↗ |
| Dec 15, 2022 | Randall B. Brenner | Chief Development & Regulatory | Sale | 29.3K | $1.97 | $57.6K | SEC ↗ |
| Dec 15, 2022 | Michael Bigham | Exec. Chairman of the Board | Sale | 51.4K | $1.97 | $101.1K | SEC ↗ |
| Nov 2, 2022 | Adam Woodrow | President & Chief Commercial | Sale | 4.6K | $3.47 | $15.8K | SEC ↗ |
| Nov 1, 2022 | Evan Loh | CEO | Sale | 8.8K | $3.47 | $30.6K | SEC ↗ |
| Nov 1, 2022 | William M. Haskel | CLO, General Counsel & Sec. | Sale | 4.4K | $3.47 | $15.2K | SEC ↗ |
| Nov 1, 2022 | Randall B. Brenner | Chief Development & Regulatory | Sale | 3.5K | $3.47 | $12.2K | SEC ↗ |
| Nov 1, 2022 | Michael Bigham | Exec. Chairman of the Board | Sale | 6.0K | $3.47 | $20.8K | SEC ↗ |
| Aug 11, 2022 | Evan Loh | CEO | Sale | 44.5K | $2.66 | $118.4K | SEC ↗ |
| Aug 11, 2022 | William M. Haskel | CLO, General Counsel & Sec. | Sale | 22.5K | $2.66 | $59.7K | SEC ↗ |
| Aug 11, 2022 | Randall B. Brenner | Chief Development & Regulatory | Sale | 19.6K | $2.66 | $52.2K | SEC ↗ |
Showing the 25 most recent of 102 Form 4 filings for Paratek Pharmaceuticals, Inc..
Most active PRTK insiders
- Evan Loh20 filings
- William M. Haskel19 filings
- Adam Woodrow17 filings
- Michael Bigham17 filings
- Randall B. Brenner14 filings
Ask anything about PRTK insider activity
Use Trabud's AI agent to query Paratek Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me PRTK CEO purchases this year" or compare it against any other ticker.
Open the AI agentPRTK insider trading FAQ
Are Paratek Pharmaceuticals, Inc. insiders buying or selling?
Paratek Pharmaceuticals, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since February 2018, Trabud has recorded 102 Form 4 filings for PRTK: 1 buys ($1.3M) and 101 sells ($8.0M). Over the full record that is net selling of $6.7M.
How many insiders trade PRTK stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Paratek Pharmaceuticals, Inc.. The most recent filing was accepted on Aug 11, 2023.
Where does Trabud get PRTK insider trading data?
All PRTK insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.